Will invite 7 temperature-controlled processing suites to accommodate numerous biologic drug requirements
Catalent, an agreement advancement and production company (CDMO), has actually increased cold chain product packaging abilities at its 200,000 square-foot Philadelphia center to support increased need for the circulation of biologic drugs, together with innovative cell and gene treatments.
Work is now underway at the center to grow the product packaging location by about 20,000 square feet, and consists of the addition of 7 brand-new temperature-controlled processing suites, which can run at either cooled or frozen conditions to satisfy the requirements of the drugs being managed. Extra ambient area has actually likewise been included for product packaging operations and products storage.
The brand-new suites include complete serialization abilities that are developed for small batches of industrial items. Recognition of the devices is anticipated to be finished by the end of Q1 2022.
” Advanced rehabs need significantly complicated handling requirements, and the financial investment we have actually made in Philadelphia permits Catalent to run effective product packaging procedures and operations, bridging the space in between scientific scale and specific niche industrial volumes,” remarks Ann McMahon, basic supervisor of industrial & & integrated advancement operations at Catalent Scientific Supply Solutions.